BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31797578)

  • 1. Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects.
    Anderson K; Xin Y; Zheng H; Yun C; Kwan E; Qin A; Namour F; Kearney BP; Mathias A
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):32-40. PubMed ID: 31797578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
    Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
    Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
    Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
    Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Thorough QT Study to Evaluate the Effects of Supratherapeutic Doses of Ledipasvir on the QTc Interval in Healthy Subjects.
    German P; Mathias A; Brainard DM; Song Q; Ling J; Kearney BP
    Clin Pharmacol Drug Dev; 2018 Aug; 7(6):641-651. PubMed ID: 29058821
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revefenacin, a Long-Acting Muscarinic Antagonist, Does Not Prolong QT Interval in Healthy Subjects: Results of a Placebo- and Positive-Controlled Thorough QT Study.
    Borin MT; Barnes CN; Darpo B; Pendyala S; Xue H; Bourdet DL
    Clin Pharmacol Drug Dev; 2020 Jan; 9(1):130-139. PubMed ID: 31468714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection.
    Namour F; Diderichsen PM; Cox E; Vayssière B; Van der Aa A; Tasset C; Van't Klooster G
    Clin Pharmacokinet; 2015 Aug; 54(8):859-74. PubMed ID: 25681059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
    Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
    Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.
    Khalilieh SG; Yee KL; Fan L; Liu R; Heber W; Dunzo E; Triantafyllou I; Hussaini A; Iwamoto M
    Clin Drug Investig; 2017 Oct; 37(10):975-984. PubMed ID: 28785879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Relative Bioavailability and Effects of Food and Acid-Reducing Agents on Filgotinib Tablets in Healthy Subjects.
    Anderson K; Zheng H; Kotecha M; Cuvin J; Scott B; Sharma S; Qin AR; Namour F; Xin Y
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):585-594. PubMed ID: 30768860
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination of olanzapine and samidorphan has no clinically relevant effects on ECG parameters, including the QTc interval: Results from a phase 1 QT/QTc study.
    Sun L; Yagoda S; Xue H; Brown R; Nangia N; McDonnell D; Rege B; von Moltke L; Darpo B
    Prog Neuropsychopharmacol Biol Psychiatry; 2020 Jun; 100():109881. PubMed ID: 32004636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supratherapeutic dose evaluation and effect of lesinurad on cardiac repolarization: a thorough QT/QTc study.
    Shen Z; Gillen M; Tieu K; Nguyen M; Harmon E; Wilson DM; Kerr B; Lee CA
    Drug Des Devel Ther; 2016; 10():3509-3517. PubMed ID: 27826183
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating Potential QT Effects of JNJ-54861911, a BACE Inhibitor in Single- and Multiple-Ascending Dose Studies, and a Thorough QT Trial With Additional Retrospective Confirmation, Using Concentration-QTc Analysis.
    Timmers M; Sinha V; Darpo B; Smith B; Brown R; Xue H; Ferber G; Streffer J; Russu A; Tritsmans L; Solanki B; Bogert J; Van Nueten L; Salvadore G; Nandy P
    J Clin Pharmacol; 2018 Jul; 58(7):952-964. PubMed ID: 29505101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the Effect of Selumetinib on Cardiac Repolarization: A Randomized, Placebo- and Positive-controlled Crossover QT/QTc Study in Healthy Subjects.
    Zhou D; So K; Dymond AW; Vik T; Al-Huniti N; Mariani G; Zorenyi G; Huang Y; Holmes V; Severin P; Rasmussen S; Martin P
    Clin Ther; 2016 Dec; 38(12):2555-2566. PubMed ID: 27837934
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of levetiracetam on cardiac repolarization in healthy subjects: a single-dose, randomized, placebo- and active-controlled, four-way crossover study.
    Hulhoven R; Rosillon D; Bridson WE; Meeus MA; Salas E; Stockis A
    Clin Ther; 2008 Feb; 30(2):260-70. PubMed ID: 18343264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Thorough QT Study of the Combination Glecaprevir + Pibrentasvir on Cardiac Repolarization in Healthy Subjects.
    Oberoi RK; Zhao W; Rosebraugh M; Mensa F; Wang H; Liu W
    Clin Ther; 2020 Jul; 42(7):1317-1329. PubMed ID: 32622784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
    Abbas R; Hug BA; Leister C; Sonnichsen D
    Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thorough QTc Evaluation and the Safety of Supratherapeutic Doses of Odanacatib in Healthy Subjects.
    McCrea J; Mostoller K; Mahon C; Liu C; Liu F; Zajic S; Panebianco D; Chakravarthy M; Brandquist C; Gutierrez M; Stoch SA
    Clin Pharmacol Drug Dev; 2019 Oct; 8(7):861-870. PubMed ID: 31175709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Exenatide at therapeutic and supratherapeutic concentrations does not prolong the QTc interval in healthy subjects.
    Darpö B; Sager P; MacConell L; Cirincione B; Mitchell M; Han J; Huang W; Malloy J; Schulteis C; Shen L; Porter L
    Br J Clin Pharmacol; 2013 Apr; 75(4):979-89. PubMed ID: 22882281
    [TBL] [Abstract][Full Text] [Related]  

  • 19. No QTc Prolongation With Zanubrutinib: Results of Concentration-QTc Analysis From a Thorough QT Study in Healthy Subjects.
    Mu S; Darpo B; Tang Z; Novotny W; Tawashi M; Xue H; Willett M; Lin L; Sahasranaman S; Ou YC
    Clin Transl Sci; 2020 Sep; 13(5):923-931. PubMed ID: 32144955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the effects of bitopertin (RG1678) on cardiac repolarization: a thorough corrected QT study in healthy male volunteers.
    Hofmann C; Banken L; Hahn M; Swearingen D; Nagel S; Martin-Facklam M
    Clin Ther; 2012 Oct; 34(10):2061-71. PubMed ID: 22980315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.